Journal of Clinical Oncology
Articles in this Issue
Strategic alignment of quality improvement interventions to address barriers to adult vaccination in oncology.
e23285 Background: To address suboptimal vaccination rates in adult patients with cancer, the American Society of Clinical...
A deep learning model for intraoperative diagnosis of lung adenocarcinoma using frozen section whole-slide images (CryoPath): A multicentric diagnostic study.
8024 Background: Intraoperative frozen section (FS) analysis is critical for guiding surgical decision-making in lung canc...
Peptide receptor radionuclide therapy with <sup>177</sup> Lu-DOTATATE in pediatric, adolescent, and young adult neuroendocrine tumors: A single-center experience from Bambino Gesù Children’s Hospital.
10027 Background: Neuroendocrine tumors (NETs) in pediatric, adolescent, and young adult (AYA) patients are rare and often...
The role of FOXM1 in regulating immune memory in triple-negative breast cancer and targeting FOXM1 to develop a therapeutic vaccine.
1119 Background: Triple-negative breast cancer (TNBC) is an aggressive malignancy with limited therapeutic options and poo...
Phase I/IIa study of DN022150, a novel selective noncovalent small molecule KRAS G12D inhibitor in patients with advanced KRAS G12D–mutant solid tumors.
3007 Background: The KRAS G12D mutation is ranks among the most common RAS mutations across human cancers and is closely l...
Long-term survival outcomes of consolidative local ablative therapy after response to first-line systemic treatment in oligometastatic NSCLC.
8601 Background: The role of consolidative local ablative therapy (LAT) for patients (pts) with oligometastatic non-small...
Chemoablation with oral erdafitinib in recurrent <i>FGFR3</i> -altered non–muscle-invasive bladder cancer: A phase II window-of-opportunity trial.
4623 Background: Non-muscle invasive bladder cancer (NMIBC) frequently recurs despite intravesical treatments, necessitati...
HIPEC combined with NIPS and tislelizumab for conversion therapy in gastric cancer with peritoneal metastasis (P0CY1 or PCI ≤10): A prospective, single-arm, phase II study.
TPS4240 Background: Peritoneal metastasis, which is common, difficult to diagnose early, and associated with a poor progno...
AI-powered assessment of tertiary lymphoid structures (TLS) from H&E whole-slide images as a prognostic tool in HNSCC.
6024 Background: Tertiary lymphoid structures (TLS) are recognized prognostic markers in Head and Neck Squamous Cell Carci...
Analytical validation of a plasma-based cfDNA NGS assay (Guardant360 Liquid CDx) for comprehensive solid tumor profiling.
3077 Background: NGS-based profiling of circulating cell-free DNA (cfDNA) enables accurate and sensitive tumor genotyping...
Induction chemotherapy plus camrelizumab followed by concurrent chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma (ImpactCRT): Long-term outcomes of a single-arm phase II trial.
4059 Background: Concurrent chemoradiotherapy (CCRT) is the standard treatment for unresectable locally advanced esophagea...
Donafenib plus immune checkpoint inhibitors with or without oral fluorouracil chemotherapy drugs (S-1/capecitabine) for patients with resected high-risk biliary tract tumor: A multi-center retrospective study.
4236 Background: Chemotherapy combined with Immune Checkpoint Inhibitors (ICIs) and donafenib showed promising efficacy an...
Efficacy and safety of capivasertib-based combination therapy in PTEN-deficient advanced or metastatic prostate cancer: A systematic review and meta-analysis.
e17058 Background: In advanced and metastatic prostate cancer, PTEN loss is a frequent change that activates the PI3K–AKT...
The ratio of levels of insulin signaling system factors and diabetes markers in the blood of patients with non-muscle-invasive bladder cancer in the absence and presence of type 2 diabetes mellitus.
e16609 Background: Components of the insulin signaling system (ISS) are involved in oncogenesis, and type 2 diabetes melli...
Integrative in silico prioritization of tumor-associated antigen pairs to support bispecific antibody-drug conjugate design in solid tumors.
e15036 Background: Antibody–drug conjugates (ADCs) are an established therapeutic modality in solid tumors, although tumor...
ctDNA kinetics throughout first-line AI and palbociclib using a tumor-informed structural variant-based ctDNA assay: Retrospective analysis of PADA-1 samples.
3050 Background: With standard assays (Limit of Detection [LoD95] at or >100 PPM), most patients with ER+/HER2- mBC sho...
Trends in lung cancer mortality among adults younger than 55 years: A CDC WONDER analysis.
e20770 Background: Lung cancer remains the leading cause of cancer-related death in the United States, with risk increasin...
Sociodemographic disparities in sepsis-associated mortality among patients with gastrointestinal malignancies in the United States, 1999-2020.
e23077 Background: Patients with gastrointestinal (GI) malignancies are increasingly treated with multimodal systemic and...
Genomic and transcriptomic correlates of deep PSA response in patients with metastatic hormone-sensitive prostate cancer (mHSPC).
5089 Background: Despite advances in mHSPC treatment with combination therapies, patient outcomes remain heterogeneous. Ac...
Lorlatinib as first-line therapy for ALK-positive advanced non-small cell lung cancer: A retrospective, multicenter, real-world study from China.
e20740 Background: The evolution of ALK tyrosine kinase inhibitors (TKIs) has led to significantly prolonged survival in p...
Predictors of in-hospital mortality among critically ill patients in ICU with cancer: A retrospective MIMIC-IV cohort analysis.
e23111 Background: Critically ill patients with cancer admitted to the intensive care unit (ICU) remain at high risk for a...
Real-world outcomes of first-line treatments in patients with metastatic non-small cell lung cancer: Final analysis of the Registurk-Lung registry.
e20633 Background: Real-world data are critical to understanding treatment patterns and outcomes in metastatic non–small c...
Gene–treatment interaction modeling to identify temozolomide-sensitive <i>IDH</i> -mutant diffuse gliomas.
2085 Background: IDH-mutant diffuse gliomas are biologically heterogeneous. While radiotherapy is standard, temozolomide (...
Sources matter: Learning to evaluate large language models for oncology treatment plans and changes observed by anchoring models to an oncology-specific database.
1617 Background: Large language models (LLMs) are increasingly evaluated for oncology decision support, yet guideline conc...
Serum magnesium level and survival outcomes in extensive-stage small cell lung cancer treated with first-line chemoimmunotherapy: A retrospective cohort study.
e20030 Background: Recent studies suggested associations between higher serum Magnesium (Mg) level and better survival out...